Position in TMO
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$1,791,135
-$342,800 QoQ
Shares Held
3,644
-30.8% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.45%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2021
11 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in TMO Over Time
Shares Held
Position Value (USD)
Position in Diagnostics & Research
Healthcare · as of Mar 31, 2026Bridgefront Capital, LLC holds $5,984,337 across 11 Diagnostics & Research names. TMO ranks #1 (29.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TMO |
Thermo Fisher Scientific Inc.
This page
|
3,644 | $1,791,135 | |
| 2 | DHR |
Danaher Corp /De/
|
5,407 | $1,025,167 | |
| 3 | A |
Agilent Technologies, Inc.
|
6,308 | $718,985 | |
| 4 | ILMN |
Illumina, Inc.
|
4,174 | $514,487 | |
| 5 | RVTY |
Revvity, Inc.
|
4,790 | $419,651 | |
| 6 | QGEN |
Qiagen N.V.
|
9,268 | $371,090 | |
| 7 | WGS |
GeneDx Holdings Corp.
|
5,412 | $347,558 | |
| 8 | IDXX |
Idexx Laboratories Inc /De
|
476 | $267,459 |
All Filings in TMO
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,791,135 | 3,644 | Shares | Sole | 2026-05-15 | |
| 2025-06-30 | $2,133,935 | 5,263 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $1,028,041 | 2,066 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $515,027 | 990 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $615,477 | 995 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $533,092 | 964 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $477,754 | 822 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $257,963 | 486 | Shares | Sole | 2024-02-14 | |
| 2023-09-30 | $255,109 | 504 | Shares | Sole | 2023-11-14 | |
| 2023-06-30 | $726,276 | 1,392 | Shares | Sole | 2023-08-14 | |
| 2021-03-31 | $1,720,096 | 3,769 | Shares | Sole | 2021-05-17 | |
| No filing history on record for this holder in this stock. | ||||||